Developmental Research Program

项目摘要 纽约大学黑色素瘤孢子发育研究计划（DRP）的总体目标是支持试点 最大限度地利用黑色素瘤新研究机会并帮助招募的项目 在助理教授或更高的水平建立癌症研究人员的翻译研究 黑素瘤DRP专注于并将选择创新和有前途的翻译研究项目， 黑色素瘤，并将监测他们的进展，以确保实现目标。DRP的主任是Iannis博士 Aifantis是纽约大学病理学系主任，也是一位国际知名的研究人员， 导师和新兴的转化黑色素瘤研究的成功完成的跟踪记录。他将 与内部评估小组和SPORE PD/PI合作，确定并支持选定的飞行员 具有卓越转化潜力的研究。纽约大学黑色素瘤孢子DRP将支持项目， 2年，使获奖者能够充分探索转化黑色素瘤新课题的潜力 research.以创新为中心，DRP将支持“高风险，高回报”的发展 黑色素瘤的研究，并鼓励提出新的方法来筛选，诊断，预后， 黑色素瘤的预测和治疗。DRP将监督所有项目和获奖者的进展情况 资金，以确保目标的实现，DRP项目可能是强有力的定位，以取代任何 SPORE项目要么没有达到其转化研究目标，要么在奖项结束前完成 期 DRP在主题和程序上与较大的纽约大学黑色素瘤孢子高度集成， 认识到SPORE增长的一个关键组成部分是继续支持和发展 黑色素瘤的新研究，特别是在改善黑色素瘤的个性化管理领域 患者NYU Langone Health（NYULH）和NYU Perlmutter癌症中心（PCC）一直致力于 使用各种试点资金机制，以支持有前途的新方法，黑色素瘤预后，临床 管理和治疗。

PROJECT SUMMARY The overall goal of the NYU Melanoma SPORE Developmental Research Program (DRP) is to support pilot projects that take maximum advantage of new research opportunities in melanoma and aid in recruiting established cancer investigators at the level of Assistant Professor or higher to the translational study of melanoma. The DRP focuses on and will select innovative and promising translational research projects in melanoma, and will monitor their progress to ensure that goals are met. The Director of the DRP is Dr. Iannis Aifantis, the Chair of the NYU Department of Pathology and an internationally regarded investigator who brings an accomplished track record of mentorship and emerging translational melanoma research success. He will work together with an internal evaluation panel and the SPORE PD/PIs to identify and support selected pilot studies with exceptional translational potential. The NYU Melanoma SPORE DRP will support projects for up to 2 years, enabling awardees to adequately explore the potential of novel topics in translational melanoma research. Focusing on innovation, the DRP will support the development of “high-risk, high-reward” investigations in melanoma and encourage proposals for novel approaches to screening, diagnosis, prognosis, prediction, and treatment of melanoma. The DRP will monitor the progress of all projects and awardees chosen for funding to ensure that goals are met and that DRP projects may be strongly positioned to replace any SPORE project either not meeting its translational research goals or completed prior to the close of the award period. The DRP is highly integrated thematically and programmatically with the larger NYU Melanoma SPORE and recognizes that a key component to the growth of the SPORE is the continued support and development of novel investigations in melanoma, specifically in the area of improved personalized management of melanoma patients. Both NYU Langone Health (NYULH) and the NYU Perlmutter Cancer Center (PCC) have consistently used various pilot funding mechanisms to support promising novel approaches to melanoma prognosis, clinical management, and treatment.